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Whither goest Kt/V? Uremia is characterized by gross contami- found an elevated blood urea and symptoms mimicking
nation of body water with a wide spectrum of retained solutes chronic nephritis in nephrectomized animals [1]. In 1826,
normally excreted by the kidney. The rationale for dialysis ther- Bostock [2] and in 1829 Christison [3] reported elevatedapy is that these retained solutes have concentration-dependent
blood urea concentrations in patients with degenerationtoxicity, which can be ameliorated through removal by dialysis.
of the kidneys. These findings were interpreted to impli-Apart from the well-established clinical consequences of abnor-
malities in fluid, electrolyte, acid base metabolism, and retained cate urea as the major toxin of uremia.
b2-microglobulin (b2m), there is very little understanding of However, the urea theory of uremic toxicity was chal-
solute-specific uremic toxicity. Evidence is reviewed to demon- lenged very early on [4]. Of particular interest to thisstrate the following: (1) Many aspects of the uremic syndrome
review was the report by Richard Bright in 1836 of pa-are controlled by adequate dialysis of low molecular weight
tients with considerably elevated blood urea concentra-solutes. (2) Urea can serve as a generic molecule to quantitate
the fractional clearance of body water by dialysis (Kt/V) of tions who did not have uremic symptoms [5]. During the
retained low molecular weight solutes. (3) Urea has no concen- latter part of the 19th century, creatinine [6], potassium
tration-dependent toxicity, and the generation rate of putative
[7], and acidosis caused by H1 retention [8] were sug-toxic low molecular weight solutes is not proportional to urea
gested to be major toxins in the uremic state. In light ofgeneration. The major clinical consequences and controversies
stemming from these interrelationships are reviewed. Kinetic the observations that numerous solutes were accumulat-
approaches to determine Kt/V dose equivalency between inter- ing in blood with renal disease, the symptom complex
mittent and continuous dialysis therapy are reviewed. We con- was termed uremia by Piorry to indicate “urine in the
clude that Kt/V can and will be generalized to describe the
blood” [9].kinetics of other solutes such as b2m as our knowledge of
Over the subsequent 160 years, many solutes haveuremic toxicity grows, and hence, it is predicted that it will
goeth and goeth and goeth. been shown to accumulate in renal failure, and a recent
tabulation by Vanholder et al of the major retained or-
ganic substances lists more than 40 compounds ranging
Our purposes for this contribution are (1) to review in molecular weight from 60 (urea) to greater than 106 D
the fundamental rationale underlying the use of urea [10]. Unfortunately, for almost all of these retained sol-
kinetic modeling and the Kt/V parameter to quantitate utes, organ-specific toxicities have not been established
dialysis therapy; (2) to review and assess the impact of in the uremic syndrome. Creatinine concentration in the
urea kinetic modeling (UKM) on dialysis therapy; (3) dialysis patient is now known to be inversely related to
to review the major controversies surrounding the Kt/V mortality and appears to be primarily useful as an index
concept over the past 30 years; and (4) to assess what of nutrition and skeletal muscle mass [11]. b2-microglob-
role there may be for the Kt/V concept in quantitation ulin (b2m) is the only organic compound accumulating
of dialysis therapy beyond the turn of the millennium. in uremia that has been established to be a major long-
term uremic toxin due to its polymerization into b2m
amyloid, which is widely deposited in bone and soft tis-UREMIC TOXINS
sues, resulting in severe multiple organ system malfunc-
The uremic syndrome is conceptualized as resulting tions [10].
in part from accumulation in body water of solutes that The abnormalities of body fluid and electrolyte com-
are normally eliminated by the kidney and have concen- position and acid-base balance in renal failure have un-
tration-dependent toxicity. The first evidence of this con- questioned adverse clinical consequences, and must be
cept was reported in 1821 by Prevot and Dumas, who controlled as well as possible for adequate dialysis ther-
apy. Hyperkalemia and hypokalemia, water and Na re-
tention, acidosis caused by H1 retention, and inorganicKey words: dialysis adequacy, kinetics, animal models, urea, body wa-
ter, normalized protein catabolic rate, CAPD, intermittent dialysis. phosphate retention can result in severe morbidity and
fatal consequences.Ó 2000 by the International Society of Nephrology
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EARLY HISTORY OF DIALYSIS THERAPY phate binders, and that adequate dialysis could not be
provided by intermittent therapy once weekly. The ad-It is clear from this brief survey that after nearly 200
vent of home hemodialysis [17] led to an empiric increaseyears of investigation, organ-specific toxicity mecha-
in the frequency of therapy to three times weekly for 10nisms are not defined for the vast majority of the many
to 12 hours with the Kiil dialyzer and resulted in muchretained solutes in renal failure. However, gross contami-
improved patient outcome. Over the next 10 years, thenation of body water with retained solutes is known to
typical dialysis dose prescribed became three timescharacterize uremia and has long stimulated efforts to
weekly treatments for six hours, irrespective of patientremove these uremic solutes in the hopes of removing
size and using the multiple point support Kiil dialyzer,“the uremic toxin(s).” Thomas Graham, a Scottish physi-
which had urea clearances about 50% higher than thecal chemist, systematically studied diffusion of solutes
original Kiil device [18].across a semipermeable membrane and coined the term
Ongoing symptomatology, especially neuropathy, de-“dialysis” in 1860 to describe the process [12]. He dia-
spite “acceptable” levels of blood urea nitrogen (BUN),lyzed a urine sample and recovered a large amount of urea,
led to speculation that larger molecular weight soluteswhich led him to speculate that dialysis might become a
[middle molecules (MMs) in the range of 1.0 to 2.0 kD]useful medical therapy. Attempts were made in 1913 to
were major uremic toxins [19, 20] and were not ade-test this notion in animals and subsequently in humans
quately removed by the thick cuprophane membranesby using a small extracorporeal dialyzer [13, 14]. How-
in widespread use in the 1960s. This led to formulationever, the first effective medical treatment of uremia by
of an empiric index of MM removal based on dialyzerdialysis was reported by Kolff et al in 1944, 84 years after
clearance of vitamin B12, a highly colored and henceGraham’s work [15]. They described complete recovery
easily measured solute of molecular weight 1.3 kD [21].from uremic coma using an extracorporeal blood dia-
High-flux membranes with greatly increased permeabil-lyzer, which they termed an “artificial kidney.” The arti-
ity in the MM range became available in the 1970s, andcle provides a fascinating documentation of a complete
a large number of small nonrandomized clinical outcomereversal of uremic coma by dialysis with the interpreta-
studies were reported between 1970 and 1985. Many oftion that, “urea is at the utmost only partly coresponsible
these studies have previously been reviewed [22]. Ap-for the clinical symptoms of uremia, but nevertheless we
proximate levels of Kt/V urea and DIB12 were calculatedchose it as a measure for the results of the dialyses. Smaller
from known dialyzer transport characteristics, blood flowmolecules will dialyze more rapidly and bigger ones less
rates, and treatment times. Review of these studies indi-so.” This statement defines with remarkable insight and
cated that clinical outcome was judged to be poor whenclarity a concept of using urea as a generic low molecular
Kt/V urea was less than 0.9, irrespective of DIB12 levelsweight solute to quantitate the dose of dialysis. This
over the range of 0.4 to 2.0, while successful outcomesconcept has been modified and refined over the interven-
was observed with Kt/V . 0.9 and 0.7 , DIB12 , 2.0.ing 55 years, but not replaced (although ultimately it will
Although these studies in aggregate did not support thebe when there is better understanding of the biochemis-
concept of a toxin in the molecular weight range of 1.0try of uremia). The thick cellophane membrane in the
to 2.0 kD, we now know, as noted previously in thisKolff/Berk rotating drum artificial kidney provided neg-
article, that b2m, an order of magnitude larger in molecu-ligible clearance of solutes larger than creatinine and
lar weight than the postulated MMs, is a major toxin inglucose, and therefore, the reversal of uremic coma in
long-term dialysis therapy.their patients by dialysis provided the first evidence after
150 years of biochemical investigations that retained low
molecular weight solutes play a critical role in the clinical NATIONAL COOPERATIVE DIALYSIS STUDY
manifestations of uremia. (NCDS), UREA, AND Kt/V
Ten years after the landmark demonstration by Scribner
EARLY SEARCHES FOR ADEQUATE that intermittent dialysis therapy could keep patients
DIALYSIS AND THE MIDDLE alive successfully and moderately well, there was little
MOLECULE CONCEPT consensus about what was an adequate dose of dialysis.
In the studies discussed previously in this article, treat-In 1960, Scribner et al reported the first successful
ment times ranged from 6 to 36 hours per week, andtreatment of chronic uremia with intermittent dialysis
there were no objective criteria to define the dose. “Un-therapy [16]. The first four patients reported in 1960
derdialysis” was entirely a clinical impression based onwere dialyzed once weekly, and major complications of
subjective interpretation of symptoms rather than anycrippling peripheral neuropathy and widespread meta-
quantifiable parameters of dosage. In an attempt to ad-static calcifications soon became apparent. These pion-
dress this problem, a conference on the adequacy ofeering studies led to a recognition of the need to decrease
inorganic phosphorous intake by diet and use of phos- dialysis was held in Monterey, California, USA, in 1975
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[sponsored by the Artificial Kidney Chronic Uremia Pro- generation rate, while in patients with protein intake in
the higher range, it was not possible to achieve pre-BUNgram (AKCUP) of the National Institute of Arthritis,
Metabolism and Digestive Diseases] [23]. All aspects of values as low as 70 because of the high rates of urea
generation. These constraints were ameliorated some-the uremic syndrome were reviewed during this three-
day conference, with the goal of developing criteria that what by the use of time-averaged BUN (TAC) for con-
centration control. With TAC targets of 50 and 90, thecould be used to guide a quantitative study of dialysis
therapy. It was concluded that there was need for a predialysis BUN targets could be liberalized to 50 to 80
and 90 to 130, which provided a good statistical separa-prospectively randomized study designed to determine
the adequate dose of dialysis dosage. The AKCUP subse- tion of the groups by the TAC definition. In fact, the
predialysis BUN also provided very good separation.quently funded a multicenter study of dialysis dose, the
National Cooperative Dialysis Study or NCDS, which The theory underlying the NCDS study design con-
tained these implicit assumptions: (1) The concentration-was concluded in 1981, and the results were published
in 1983 [24]. The NCDS was a powerful study that was dependent toxicity of all low molecular weight solutes
was directly proportional to the generic solute modeled,designed to examine the role of both low and middle
molecular weight solute removal in dialysis therapy. urea; and (2) the generation rates of all of these solutes
were identical to the generation rate of urea.Urea nitrogen served as a generic low molecular weight
toxic solute, and treatment time served as a surrogate for In part, these relationships appeared to be validated
since the low BUN Groups I and III had much betterMM removal. Low and high BUN levels were prescribed,
and short and long treatment times (t) were prescribed outcome than the high BUN Groups II and IV [27].
However, a major flaw in the assumption that uremicfor both the low and high BUN groups. Thus, there
were four treatment groups: (Group I) low BUN, long toxicity was directly proportional to BUN was apparent
in the NCDS results when the probability of failure (PF)t; (Group II) high BUN, long t; (Group III) low BUN,
short t; and (Group IV) high BUN, short t. was mapped as a function of BUN and NPCR at the
end of data collection [28]. The probability of failureThe variable-volume, single-pool (VVSP) urea kinetic
model was used to prescribe and monitor both the dial- was sharply increased in the high BUN Groups II and
IV compared with low BUN Groups I and III patientsysis prescriptions and the dietary protein intake [normal-
ized protein catabolic rate (NPCR) g/kg/day] [25]. In (52 vs. 13%) for patients in whom the mean NPCR was
adequate, that is, greater than or equal to 0.8 g/kg/day.this way, prospective, randomized levels of BUN were
held relatively constant by appropriate adjustment of the In contrast, the probability of failure was very high (75%)
in all patients with NPCR , 0.8, irrespective of the leveldialysis prescriptions, and levels of protein intake were
regularly monitored (normally weekly) to keep within of predialysis BUN, which ranged from 50 to 110 mg/dL
in this group of patients.the limits of 1.1 6 0.3 g/kg/day by dietary counseling. It is
interesting to note that this feedback process—in which This sharp dichotomy in the relationship between
probability of clinical failure, BUN, and NPCR was verydelivery of treatment and nutritional status were moni-
tored weekly and steps were taken to address any defi- puzzling until the results were analyzed as a function of
BUN, NPCR, and the dose of dialysis expressed as theciencies—now serves as the kind of model used for Con-
tinuous Quality Improvement (CQI) initiatives. total treatment clearance of urea as a fraction of body
water, that is, Kt/V, the product of dialyzer urea clear-Although there was a relatively small number of pa-
tients (160 distributed between the 4 arms) and outcome ance (K) and treatment time (t) divided by the urea
distribution volume (V). The term K/V describes thewas observed over a relatively short time (6 to 12
months), the NCDS remains the only prospectively ran- rate of change in solute concentration during dialysis,
and Kt/V when expressed as an exponent represents thedomized clinical study of dialysis therapy reported 40
years after the first report of long-term dialysis for integral of K/V over the entire treatment, and describes
the total change in concentration over the treatment [25].ESRD. The National Institutes of Health funded a multi-
center HEMO study currently under way that is targeted The Kt/V parameter can be used to quantitate the effect
of dialysis treatment on any solute when appropriatefor completion in 2001. It will be the second large ran-
domized and feedback-controlled study [26]. measurements are made to determine dialyzer clearance,
distribution volume(s) and kinetics in the body, and gen-The original study design called for dialysis doses cal-
culated to control midweek predialysis BUN at 70 in eration rate for the solute. Although up to now it has
been applied mostly to urea representing a generic lowGroups I and III and at 110 mg/dL for Groups II and
IV. The NPCR was targeted in the range of 1.1 6 0.3 molecular weight uremic toxin, it can equally well be
used to study other solutes such as creatinine and b2m.g/kg/day, but ranged from 0.6 to 1.4 in individual patients.
In patients with protein intake in the lower range, it was The analysis with BUN, NPCR, and Kt/V showed that
all patients with Kt/V , 0.8 had a high probability ofvery difficult to reduce the dialysis dose sufficiently to
achieve BUN values at 110 because of the very low urea failure irrespective of BUN or NPCR. The Kt/V model-
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Fig. 2. Comparison of Keshaviah analysis of NCDS with final dataFig. 1. Adequate dialysis defined by Kt/V and studied in the National
tapes to the original analysis with “raw data.” Symbols are: (h) GotchCooperative Dialysis Study (NCDS) ranges from 0.9 to 1.5 depending
and Sargent; (j) Keshaviah. Note that the exponential curve fits of theon the normalized protein catabolic rate (NPCR).
two analyses are virtually identical. The difference in the two data sets
is a somewhat different distribution of the patients with high failure
rates for spKt/V , 0.8. The data are very similar for 0.9 , spKt/V , 1.5.
ing construct considered urea as a generic solute only to
define the magnitude of normalized clearance provided
for retained low molecular weight compounds. It con- shown in Figure 2. We reported linear, exponential, and
step function fits to the data. Both our exponential fittained no assumptions about proportionality between
and the Keshaviah curve fit are shown in Figure 2, whereurea and other low molecular weight compounds with
the curves can be seen to be virtually identical and r wasrespect to concentration-dependent toxicity and genera-
0.86 for both data sets. The differences in data distribu-tion rate.
tion are almost entirely confined to the region of highThe conclusions resulting from that analysis [28] are
failure rate with spKt/V , 0.8 where apparently thereproduced in Figure 1, where the family of curves relat-
success-failure code was changed for some of these pa-ing midweek predialysis BUN to NPCR as a function of
tients after completion of the study. The data distribu-Kt/V is displayed. There was a fourfold increase in the
tions are virtually identical over the critical domain ofprobability of failure for all patients with single-pool
0.9 # spKt/V # 1.5. In retrospect, the strength of theKt/V (spKt/V) , 0.8 compared with patients with spKt/V
NCDS was primarily in showing the greatly increased0.9 to 1.6. In light of these findings, in 1985 we developed
risk of failure for spKt/V , 0.8. The sample size wasthe modeling line shown in Figure 1 (see bold line labeled
probably too small to really define outcome on the shal-1985), which defined the minimum adequate dose of
low part of the curve with spKt/V . 1.0, which is consid-three times weekly dialysis to be spKt/V 1.0 for NPCR #
erably more difficult to assess.1.1 and required spKt/V to increase almost linearly with
The results of a recent cross-sectional analysis of twohigher levels of NPCR in order to stay within the coordi-
large databases [30] are depicted in Figure 3, where thenates of the domain studied in the NCDS. Thus, in pa-
relative risk (RR) of mortality is shown as a function oftients with a mean NPCR of 1.4, the 1985 modeling line
the equilibrated Kt/V (eKt/V), the spKt/V value correctedwould require spKt/V of 1.4.
for rebound, as discussed later in this article. The data-
base analyzed in Figure 3 (15,000 patients) shows that
SUBSEQUENT COMPARATIVE STUDIES OF Kt/V eKt/V reached a minimum and constant level at eKt/V 5
The NCDS data were reanalyzed in 1993 by Keshaviah 1.05, which corresponds to an average spKt/V of 1.2. The
using the final edited data tapes [29]. Our analysis was National Kidney Foundation-Dialysis Outcomes Quality
based on the complete kinetic database archived at the Initiative (DOQI) Hemodialysis Adequacy work group
kinetic control center and the success-failure code for recently reviewed all hemodialysis clinical outcome data
each patient at the end of the study. Keshaviah concluded for the development of clinical practice guidelines [31].
that his reanalysis fit the probability of failure to spKt/V The result of this review was a recommendation that the
better as an exponential function compared with the step minimum adequate spKt/V should be a spKt/V 1.2, which
function, which we believed indicated maximum benefit is depicted as a second modeling line in Figure 1, labeled
1997. Thus, 12 years after the mechanistic analysis ofwith spKt/V $ 1.0. The two data sets and analyses are
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Fig. 3. Normalized relative risk of mortality (nRR) as a function of
equilibrated Kt/V delivered (eKt/Vd). Large solid squares are Owen and
small solid squares are USRDS data. (Reprinted from Am J Kidney Dis
30:1–15, 1997 with permission from the National Kidney Foundation.) Fig. 4. An illustration of the influence of Kt/V dispersion on assessment
of mean Kt/Vs in a patient populations. The mean will be meaningful
only if therapy is individualized to assure that Kt/Vs for all patients
distribute over a narrow range.
the NCDS was published, the spKt/V modeling line for
adequate dialysis was increased from 1.0 to 1.2, which
moves it into the middle of the adequate domain defined
by the NCDS. However, the confidence limits on the
locus of this modeling line are still quite broad 15 years
after the mechanistic analysis of the NCDS.
Two recent cross-sectional database analyses have
been interpreted to show that minimum mortality ex-
pressed as the standard mortality ratio (SMR) requires
an eKt/V of 1.2 to 1.3 and a spKt/V 1.4 to 1.6 [32, 33].
However, in both of these studies, eKt/V values for indi-
vidual patients were normally distributed over a very
wide range that resulted in a correlation of each mean
eKt/V to SMR [30]. From the nonlinear relationship of
outcome to Kt/V apparent in Figure 3 and the broad
range of individual eKt/V values contained in these ob-
servations, one would expect nonrandom failures for
individual patients depending on their individual treat-
Fig. 5. The HEMO study should provide a definitive database forments (that is, patients with very low eKt/Vs would have
analysis of relative risk of mortality (RRM) as a function of Kt/V andhigher mortality than those with very high values). It
V over the shallow segment of the curve.
can be concluded that the average eKt/V the authors
suggested that was required to reduce the SMR and was
inferred to apply to all patients, would be substantially
greater than was actually needed. This conclusion results randomized study (the HEMO study) [26] of clinical
from the profound effect of inadequate Kt/V values outcome with four treatment arms has been underway
(Kt/V , 0.8) contained in the widely varied treatments now since 1995 and is due for completion in 2001. In
analyzed and contributes disproportionately to the ob-
this study, clinical outcome with eKt/V of 1.05 (spKt/V
served SMRs. Evaluation of the effect of eKt/V disper-
1.21 to 1.35) is compared with that with eKt/V 1.45sion in the Hakim et al and Parker et al data suggests
(spKt/V 1.65 to 1.85), and both eKt/V levels includethat the maximum levels of eKt/V and spKt/V actually
low- and high-flux dialyzers. The randomized therapyevaluated were in the range of 1.05 and 1.2, respectively
domains for this study are shown in Figure 5. It can be[32, 33], and are therefore consistent with the results in
confidently predicted that this study will provide a muchFigure 3. The effect of dose dispersion is illustrated in
more definitive evaluation of the flat segments of theFigure 4. If therapy is individualized for each patient,
outcome curves in Figures 2 and 3 and hopefully quanti-the distribution will become narrower, and the outcome
tate the value of prescribing high eKt/V with thricerelative to mean Kt/V will become more realistic.
It should also be noted that the large prospectively weekly hemodialysis.
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IMPACT OF THE NCDS ON DIALYSIS were not well understood for many years after its publi-
cation in 1985. It was widely believed for several yearsTHERAPY IN THE UNITED STATES
after the NCDS results were published in 1983 that theThe analyses of the NCDS had profound implications
adequacy of the dialysis prescription could be evaluatedwith respect to conceptual modeling of the dialysis dose
from the predialysis BUN or TAC value alone. Theusing urea as a generic low molecular weight solute.
initial report from the NCDS suggested that the studyKolff considered the amount of urea removed to be a
had resolved the controversy started by Bright in 1836measure of the dose. The design of the NCDS considered
and finally shown that clinical uremia was causally re-urea concentration to be a surrogate for low molecular
lated to the level of BUN [27]. This conclusion, stemmingweight uremic toxins whose toxicity was directly propor-
from the BUN target study design, dominated treatmenttional to urea concentration and whose generation was
recommendations in the final report. It was recom-proportional to urea generation. That is, the dose of
mended that to implement the results of the NCDS, thedialysis must be increased as a function of NPCR to hold
dialysis team should first select a target BUN (or TAC,BUN targets constant. The results in Figure 1 show that
an unmeasurable quantity) and measure or select anthe dose is best modeled as the fractional clearance of
adequate NPCR [34].body water or Kt/V of the generic low molecular weight
In contrast, the mechanistic analysis showed that BUNsolute urea. The complete lack of correlation between
was totally irrelevant with respect to adequacy of thespecific levels of BUN and outcome (domain X in Fig. 1)
dialysis prescription, and that measurement of Kt/V andshowed that uremic toxicity was unrelated to BUN, par-
NPCR was mandatory for assessment of therapy. Severalticularly at low levels of protein catabolism. The study
years after publication of the NCDS results in 1983, itdid show that there is a low molecular weight clearance
was often recommended that dialysis therapy could bethreshold, described by Kt/V, below which one should
adequately monitored from BUN alone [35–37] and thatnot go. The findings in domain X (Fig. 1) clearly demon-
Kt/V was an error-prone monitoring methodology [38].strated that the two primary assumptions underlying the
The most recently reported recommendation to monitor
NCDS study design, namely, that concentration-depen-
the dialysis prescription from predialysis BUN alone was
dent toxicity and generation rates of toxic low molecular in 1998 [39].
weight solutes are directly proportional to the generic The publication of the NCDS results in 1983 coincided
solute urea, were invalid. The NCDS results also indi- with implementation of the sharply reduced composite
cated that there was no adverse effect of shortened treat- rate for reimbursement of dialysis treatment in the
ment time on probability of treatment failure. There was United States by the Health Care Financing Administra-
a marginal association between t and failure (P 5 0.06), tion (HCFA). Analysis of HCFA mortality data pre-
but there was also a definite inverse correlation between sented at the Morbidity, Mortality, and Prescription of
Kt/V and t; that is, the Group I patients received a some- Dialysis Symposium (MMPS) in 1990 [40] showed that
what greater Kt/V than the Group III patients (1.16 the gross mortality rate in the Unites States began to
vs. 0.96) [29]. Thus, the marginal effect of t is readily increase quite sharply in 1983 despite no change in the
explained by a small difference in dose close to the transi- rate of increase in major risk factors [41]. Data presented
tional region or steep segments of the outcome curves at that meeting by National Medical Care (which pro-
in Figure 2. The combination of this result with the unfor- vided dialysis for about 25% of all patients in the US)
tunate interpretation that adequacy of the prescription indicated that only predialysis BUN was used to monitor
could be monitored from BUN alone [27, 34] set the therapy routinely [11]. An analysis of visiting patients in
stage for reducing treatment time in patients with low San Francisco indicated that in 98% of patients, only
BUN due to low NPCR with disastrous results, as dis- predialysis BUN was measured and that low treatment
cussed later in this article. time correlated with low BUN and low Kt/V in this
We considered Kt/V urea to be the fundamental defi- patient population [42]. Thus, it appears that both the
nition of dose prescribed with respect to removal of academic and clinical nephrology communities in the
low molecular weight materials, and hence to define the United States interpreted the NCDS to show that clinical
mechanism of uremia control by dialysis in the NCDS. uremia was proportional to BUN and that treatment
Although this analysis was complete and a manuscript time could be reduced if BUN was low. The results of
was written for inclusion in the NCDS publication in reported U.S. Renal Data System data for 1986, 1990,
1983, the mechanistic analysis was rejected by the NCDS and 1991 [43] and calculated values from core indicator
coordinating staff, and thus, it was not included in the results for 1996 [44] are depicted in Figure 6, where
supplement but was accepted as a peer-reviewed article they are expressed as cumulative frequencies of eKt/V
in a regular issue of Kidney International in 1985, two (discussed later in this article) along with recently re-
years later [28]. The implications of the Kt/V analysis ported relative risk of mortality [30] and the approximate
domains of the four NCDS study groups. Note that me-with respect to evaluation of the adequacy of dialysis
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Fig. 7. A perspective on the perceived role of urea in uremia over the
past 180 years.
Fig. 6. The dialysis dose in the United States from 1986 to 1996 com-
pared with NCDS Group I and IV and Group I and III patients. Symbols depicted in Figure 7, was likely a consequence of inter-
are: (small solid circle) 1986; (d) 1990; (h) 1991; (r) 1996); heavy solid preting the NCDS to show that the adequacy of dialysisline, relative risk of mortality.
therapy could be monitored from measurement of BUN,
and that treatment time was not an important determi-
nant of outcome. The ever-increasing economic pres-
dian eKt/V ranged from 0.75 to 0.85 in 1986 to 1991 U.S. sures combined with this interpretation of the NCDS
Renal Data System samples. The median finally reached resulted in a reduction of treatment time, the single most
1.0 in the 1996 Core indicator data, but still, 50% patients costly component of the prescription, in patients with
had levels less than 1.0. These data indicate quite severe low BUN due to low NPCR, and led to the syndrome
underdialysis in the United States for many years after depicted in the lower left corner of Figure 7, which un-
the initial publication of the NCDS results as well as doubtedly contributed to the increased mortality in the
after publication of the subsequent mechanistic analysis. United States in the 1980s.
The curves in Figure 6 would predict an increase of
relative risk of mortality by more than 50% for half of
KINETIC LIMITATIONS OF THE NCDSthe patients over the interval 1986 to 1990.
In the light of these data, three different historical The study was done with low-flux and relatively low-
efficiency dialyzers with relatively long treatment timesperceptions of the role of urea in uremia can be described
as shown in Figure 7. In 1820, high BUN and chronic and was analyzed with a single-pool, variable-volume
urea kinetic model. With the advent of high-flux, high-nephritis were initially observed to correlate with clinical
uremia. If we consider Kt/V an analogue of residual renal efficiency dialyzers, it has been recognized that double-
pool kinetic modeling is required to account for postdial-function normalized to patient size, the patients de-
scribed in 1820 would be mapped in the domain of low ysis urea rebound, which is more significant at higher
rates of dialysis. The double-pool nature of urea kineticKt/V, low NPCR, and high BUN, as depicted in Figure 7,
that is, patients with far advanced renal failure, anorexia, behavior classically has been considered to represent
diffusion between the intracellular and extracellular ana-and reduced protein intake. In contrast, Bright’s patients
with elevated BUN and minimal clinical abnormalities tomic compartments of body water [47]. More recently,
it has been considered that the second compartment iscan be predicted to have had a higher level of residual
renal function with less impairment of appetite and primarily skeletal muscle water and that transfer is lim-
ited by blood flow to this large compartment of bodyhigher protein intake, and would thus likely fall in the
domain of higher Kt/V, higher protein intake, and ele- water [48]. In either event, intercompartmental transfer
can be modeled as a concentration gradient-driven diffu-vated BUN, as depicted in Figure 7. A dialysis therapy
analogue of this description of Bright’s patients has in sion process characterized by a first-order transfer coef-
ficient, which is exactly analogous to dialysance in thefact been reported, which underscores the lack of corre-
lation between BUN and clinical uremic toxicity [45, 46]. dialyzer. The magnitude of end dialysis dysequilibrium
between the compartments will be primarily dependentA third perception of the role of urea in uremia, the low
NPCR, low BUN and low Kt/V syndrome of the 1980s on the ratio of dialyzer clearance to the body transfer
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coefficient and the relative sizes of the two compart- results indicate that for very short treatment times of
less than two hours, the Tattersall algorithm provides aments. Three independent studies have recently shown
that the magnitude of rebound is a highly predictable better estimate of rebound.
There are also errors in calculated total urea distribu-empiric function of the rate of dialysis [48–50]. The Tat-
tersall et al formulation to predict the equilibrated Kt/V tion volume as a function of the level of spKt/V delivered,
which were not considered in kinetic control of the(eKt/V) after rebound is [49]
NCDS. It has subsequently been recognized mathemati-
eKt/V 5 spKt/V[t/(t 1 35)] (Eq. 1)
cally and verified clinically that the volume calculated
with the VVSP model is quite accurate in the range ofwhere t is treatment time in minutes, and tp is “patient
spKt/V 1.0 to 1.2, but that V is progressively underesti-clearance time” (35 min).
mated as spKt/V falls below 1.0 and that V is progres-The empiric Daugirdas/Schneditz formulation [48] is:
sively overestimated as spKt/V rises above 1.2 [22, 49].
eKt/V 5 spKt/V[(t 2 36)/t] 1 0.03 (Eq. 2) Consequently, it is very likely that the spKt/V values
,1.0 in the NCDS were overestimated by 5 to 10%, andwhere t is treatment time in minutes.
the doses .1.2 were underestimated by about 5%. TheBoth of these formulations have been confirmed with
errors in volume with low and high spKt/V would notclinical data over the typical ranges of clinical spKt/V
significantly affect the analysis of the NCDS, but would[49, 50]. In anatomical terms, it can be demonstrated
be of much greater importance in prescription and analy-that these relationships would result with the typical one-
sis of low spKt/V doses with more frequent dialyses, andhalf ratio of extracellular to intracellular volume and a
will require appropriate algorithms to correct the VVSPwhole body transfer coefficient of 15 mL/min/L of total
volume.body water. However, the two expressions will give quite
different results with very short treatment times, which
are now being studied with daily dialysis. Equation 1 can TREATMENT TIME AS AN INDEPENDENT
be divided by equation 2 with eKt/V held constant to DOSE PARAMETER
evaluate the spKt/V required as time decreases. Thus,
The effect of treatment time per se has long beenneglecting the small constant 0.03 in equation 2, we have:
hotly and emotionally debated. Locatelli and Manzoni
recently commented that “the history of dialysis teachesspKt/VDaug/spKt/VTatt 5
t
t 1 35
3
t
t 2 36 us that a reduction in dialysis time in the USA was accom-
panied by a reduction in life-expectancy” [51]. Scribner
(Eq. 3)
has recently interpreted the high mortality in the United
States recognized in the 1980s and 1990s to be due toThe solution of equation 3 shows that the (spKt/
Vdaug)/(spKt/Vtatt) ratio is virtually identical until t shortening of treatment time [52] and attributes shorten-
ing of treatment time to be a direct consequence offalls below 120 minutes. At t 5 60, the ratio is 1.58,
which does not pose a significant issue with current three the mechanistic analysis of the NCDS, indicating that a
spKt/V of 1.0 was adequate and there was no improve-times weekly dialysis treatment times. However, if used
for studies of ultrashort daily dialysis, the Daugirdas/ ment with higher levels of spKt/V. Dr. Scribner’s inter-
pretation is particularly ironic to us in the light of (1)Schneditz algorithm would require 58% greater spKt/V
for any given targeted eKt/V compared with the Tatter- data presented in Figure 4 showing median eKt/V levels
0.7 to 0.8 five years after the Kt/V interpretation wassall algorithm. The validity of these two algorithms at a
very short treatment time was evaluated with the classic published, and (2) data presented at the Dallas Morbid-
ity, Mortality and Prescription of Dialysis Symposiumdouble-pool model [24] with volume ratio one half, as
noted previously, and whole body transfer coefficient (MMPS) in 1990 (also 5 years after the Kt/V analysis
and the onset of increasing mortality rate in the United15 mL/min/L to calculate both postdialysis BUN and
rebound, so that spKt/V and eKt/V could then be com- States), indicating that 98% of prescriptions were not
based on Kt/V [40] and that only predialysis BUN wasputed from the variable-volume, single-pool model. Cal-
culations were made over a range of t from 240- to 60- monitored [39]. Scribner quotes the truly remarkable
low mortality with eight-hour three times weekly dialysisminute results compared with eKt/V calculated with the
Tattersall and Daugirdas/Schneditz algorithms. Both al- reported by Charra et al [53] to support his conclusion
that very long treatment times are required for adequategorithms predict the double-model analytic solutions
very well until t falls below 120 minutes. At a lower t, dialysis. We have previously reported a comparison of
our mortality with very short mean treatment time ofthe Tattersall equation continues to agree closely with
model solutions, but the Daugirdas/Schneditz equation 2.3 hours (abstracts; Uehlinger et al, J Am Soc Nephrol
2:A352, 1991; Uehlinger et al, J Am Soc Nephrol 4:A392,substantially underestimates eKt/V relative to both the
analytic solutions and the Tattersall algorithm. These 1993) [41] to age- and diabetes mellitus-adjusted registry
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Fig. 8. Comparative mortality rates. The lowest normalized mortality
rates were found with the longest and shortest treatment times.
Fig. 9. Does a J curve for RR 5 f(Kt/V) observed in cross-sectional
analysis prove Kt is the optimal dose parameter?data reported at the MMPS [40, 54–56]. The results are
shown in Figure 8, where it can be observed that the
two lowest mortality rates resulted with the longest and
shortest treatment times, which must raise serious ques-
condition with a V of 40 L? Small patients tend to have
tion about the importance of time per se as a generalized
substantially higher weight gains relative to size than
dose parameter independent of its role in Kt/V. There
large patients, so greater oscillations of Na and water
are undoubtedly some patients with high weight gains
balance might also contribute to higher morbidity. In
and/or severe heart disease who will require longer treat-
our experience, NPCR is higher in small patients, so thement times for optimal control of sodium and water
rate of H1, urea, and other nitrogen catabolite loadingbalance, as recently reviewed by Levin [57]. There is no
relative to V would also be higher. In well-muscled pa-question that shortening of treatment time in the United
tients, the large pool of muscle water may not be aStates in the 1980s and 1990s was associated with in-
significant source of toxins and may provide a capaci-creased mortality, but it was clearly associated with de-
tance to reduce the metabolic fluctuations of uremia,creased Kt/V, and the effects of short t can not be sepa-
that is, concentration changes or “unphysiology.” Noterated from the effects of low dose. The data in Figure 7
that the modeling lines in Figure 1 are discontinuous atindicate that time can be substantially reduced, but only
NPCR 5 1.1 and indicate that a larger dose of dialysiswith assurance that adequate Kt/V is both prescribed
is required with patients with higher NPCR, which inand delivered. In our view, adequate dialysis is more
our experience with monthly UKM for over 20 yearsdependent on quality of treatment time than on total
will often be the smaller patients with lower levels of V.treatment time.
It has been argued recently that the correlation of
mortality with V invalidates Kt/V as a parameter of dose
EFFECT OF V ON MORTALITY since Kt (the total amount of clearance) and V relate to
mortality inversely [58, 60]. Thus, at any level of Kt,It has recently been reported that the urea distribution
Kt/V decreases as V increases, and therefore, Kt shouldvolume (V) is an independent predictor of mortality
be considered independently as a parameter of dose. It(abstract; Uehlinger et al, J Am Soc Nephrol 4:A392, 1993)
has been recommended following this logic that a Kt of[58, 59]. We observed volume to be the most powerful
42 L is the optimal prescription for all female patientspredictor of outcome in the NCDS database, but the
and that 48 L is optimal for all male patients irrespectiveobservation was not reported nor pursued further. The
of size and volume. The evidence presented to supportphysiologic mechanism(s) underlying the dependence of
this is the observation that mortality risk computed inmortality on V is not well defined. It has been suggested
cross-sectional analysis falls and reaches a gender-depen-that V is a surrogate for nutrition [58, 59], but there
dent minimum in these ranges [58], while mortality as aare not sufficient data available to separate malnutrition
function of Kt/V tends to show a J-shaped curve [61].from small body size in the databases analyzed to date.
This is illustrated in Figure 9A, in which the relative riskFor example, does a small female patient in excellent
of mortality reaching a minimum at 45 L is depicted, whilephysical condition but with a V of 20 L have greater
mortality risk than a large male patient in equally good Figure 9B, a J-shaped curve for relative risk as a function
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Fig. 10. The RR profiles expected if optimal therapy for all patients
is Kt 5 45 L.
Fig. 11. The RR profiles expected if Kt/V 5 1.2 is optimal therapy for
all patients.
of Kt/V is inscribed, that is, a mathematical minimum,
and results in dosing ambiguity. Unfortunately, cross-
sectional analysis of outcome data is a flawed method
to study this question, since Kt and V are not clearly the level achieved is V dependent; that is, small-volume
separated. The only rigorous way to examine these rela- patients will have higher mortality risk at all Kt/V. How-
tionships is stratification of the data base by V [62, 63] ever, this database is relatively small and cannot give a
and analysis of relative risk as a function of Kt and Kt/V definitive answer as to whether the minimum relative
over a range of constant V, as illustrated in Figure 10. risk may be both V and Kt/V dependent. The HEMO
If there is a constant Kt that is optimal for all patients, study illustrated in Figure 4 should provide very valuable
curves such as those in Figure 10A will be seen with a information bearing on this question, since it will be
relative risk reaching a minimum at 45 L for all V, but comprised of a database prospectively randomized to
with the minimum relative risk inversely proportional to two very different levels of tightly controlled eKt/V for
V. If this were found, it is absolutely predictable that all V. Thus, unlike a cross section of current therapy in
the second family of curves shown in Figure 10B must which patients with large V typically have lower Kt/V
also be observed. If the results in Figure 10A are seen, the and patients with small V have high Kt/V (the explana-
point of minimum RR cannot be constant as a function of tion for a J-shaped curve of outcome with respect to
Kt/V, but in fact must occur at points defined by 45/V Kt/V), the HEMO data should permit examination of
for each cohort of V analyzed, as shown in Figure 10B. outcome with Kt/V independent of confounding by V.
In contrast, if the dose is best described as Kt/V rather
than Kt, the two families of outcome curves seen in
ATTEMPTS TO SIMPLIFY UREAFigure 11 must be observed. Here, it is apparent that
KINETIC MODELINGthe relative risk is minimized at Kt/V 1.2 for all V, but
Formal UKM requires accurate values for the primaryis minimized at variable Kt levels that are defined by
treatment parameters—dialyzer clearance, treatment time,1.2(V) for each cohort of V. Analysis of U.S. Renal Data
ultrafiltration rate, and the predialysis and postdialysisSystem data stratified by V has been reported by Wolfe
BUNs (Co, Ct)—to input into a computer program foret al [59] and shows curves consistent with Figure 11A,
solution of the modeling equations to calculate Kt/V.indicating Kt/V to be the preferable dose parameter.
Since the major determinant of the Kt/V is Ct/Co, severalAnalyses such as those illustrated in Figures 10 and 11
authors have developed approximation equations to sim-are required to study the relative merits of Kt and Kt/V
plify analysis of Ct/Co without the need for formal UKMas generalized dialysis dose parameters. The U.S. Renal
Data System data suggest that minimal relative risk may [64–68]. The Daugirdas equation is the only one of these
approximation equations that accurately predicts spKt/Vbe achieved at fairly similar Kt/V levels for all V, but
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over a fairly wide range of dosage [64]. It incorporates options are many: (1) Should time be changed and how
much? (2) Should blood and/or dialysate flow be changeda treatment time-dependent estimate of urea generation
and an ultrafiltration value for the individual treatment and how much? (3) Is there reason to suspect dialyzer
clotting or access recirculation and how much? (4) Areanalyzed.
There is one serious limitation of the Daugirdas equa- laboratory errors and/or sample drawing the most likely
cause of dose error? (5) Should a different dialyzer betion: It is often used only to estimate spKt/V. In this case,
there is no way to evaluate postdialysis BUN sampling used and what transport capacity (KoA) is indicated? It
is very easy to navigate this tangled technical domainerrors, most of which will cause a spurious increase in
the estimated spKt/V. If there is recirculation and the and select the best options for correction of the prescrip-
tion with appropriate urea kinetic analysis programs, butblood pump is not reduced to about 70 mL/min for 15
seconds prior to drawing the sample, a spuriously low Ct it is very difficult to choose empirically between these
many parameters. With the advent of earlier initiationand high spKt/V will be calculated. If a venous sample
is drawn in error, again a spurious high spKt/V will be of dialysis, patients will likely be started on dialysis at
higher levels of residual renal function. It is essential incalculated. Formal UKM is based on calculation of the
urea distribution volume (V), and errors such as those our view to use urea kinetic modeling in an attempt to
quantitatively sum the renal and dialyzer components ofnoted previously in this article will be readily apparent
by the spuriously low V calculated. The Daugirdas spKt/V the prescription.
Although some of the approximation equations re-equation can be used with routines to calculate the dialyzer
urea clearance (Kdu) from KoA, Qb, Qd, and Qf, which will viewed previously in this article serve a very useful pur-
pose in both clinical therapy and research [48–50, 64, 69],permit calculation of V from the Kd(t) product divided by
the spKt/V estimated with the approximation equation. in other instances, they violate a fundamental law of sci-
ence that “everything should be made as simple as possi-However, in this case, all data required for formal UKM
are assembled, and appropriate software is required for ble, but not simpler” (Albert Einstein, in Readers Digest,
the calculations. Thus, there seems little reason not to October, 1977).
do more rigorous data analysis with formal UKM.
The urea reduction ratio [URR; 100(1 2 Ct/Co), %] NORMALIZED PROTEIN CATABOLIC RATEhas been used to assess mortality rate in a large database
Approximately 90% of waste catabolite nitrogen accu-[61]. It is a very inexpensive parameter to obtain, and
mulating in body water in uremia is urea. The urea nitro-for this reason (since UKM was still not widely used 17
gen generation rate can be readily calculated from ureayears after the NCDS report), the HCFA has required
kinetic modeling [24], and nitrogen balance studies haveall facilities to report URR values in order to obtain a
shown this to be quantitatively related to the net ratemaximum number of patients for whom some measure
of protein catabolized to waste nitrogen [68]. A usefulof dialysis dose is available. Since the Kt/V calculation is
approximation equation has also been developed to esti-strongly related to Ct/Co, the URR provides a reasonable
mate NPCR quite accurately [69].estimate of dose for statistical analysis of outcome in large
There is always some mathematical linkage betweendatabases and can be used with population constants to
Kt/V and NPCR, since in the urea kinetic model theestimate spKt/V and eKt/V for large patient populations
same set of predialysis and postdialysis BUNs (Co, Ct) are[30]. However, spKt/V cannot be reliably calculated for
used to calculate V and urea generation rate (Gu). Theindividual patients from URR since it contains no ultra-
raw data BUN input to the V calculation is Ct/Co and tofiltration or urea generation estimates, and therefore, it
the Gu or PCR calculation the input is (Co 2 Ct) [25].is not adequate to monitor the delivered dose of dialysis
Since Kt/V is inversely related to Ct/Co and PCR is di-in individual patients. Patients who consistently require
rectly related to (Co 2 Ct), any error in Ct will result inhigh rates of ultrafiltration may have fully adequate
linked errors in Kt/V and NPCR. If the Ct is spuriouslyspKt/V but low URR, since the effect of ultrafiltration
low because of sampling error from taking a venous sam-on the URR cannot be determined. The URR is an
ple or with unrecognized recirculation effect present, spu-approximate correlate of spKt/V, but there is no way to
riously high values for both Kt/V and NPCR will bejudge sampling errors, as discussed previously in this
found. However, the error in V should provide a reliablearticle, and the rate of dialysis cannot be quantitated to
guide to this problem. At high rates of dialysis, the Ctpredict the amount of rebound and calculate the eKt/V.
will be low relative to the equilibrated value after rebound,All of the simplified approaches to UKM, but particu-
and if single-pool kinetics are used, spuriously high Kt/Vlarly the URR, neglect two very important aspects of
and NPCR relative to the equilibrated values will beformal UKM, namely, the ability to quantitatively analyze
seen. However, analysis of data with formal UKM tonondelivery of treatment and to quantitatively adjust
calculate and evaluate V and correction for double-pooldialysis prescriptions. If the delivered spKt/V deviates
significantly from the targeted level, the dose adjustment effects should provide correct assessment of these effects.
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Several authors have reported a significant correlation of spKt/V prescribed each treatment have varied from
0.3 to 1.7, treatment time from 1.5 to 8 hours, and fre-between Kt/V and NPCR using random numbers for Ct
and Co [70–72]. Greene, Depner, and Daugirdas have quency of four to six times per week. The clinical reports
all indicate improved outcome irrespective of the levelcarefully analyzed the mathematical linkage issue and
point out that random numbers do not simulate what of Kt/V, which has led some to conclude that Kt/V is a
badly flawed parameter to define adequacy of the dialysishappens in dialysis [73]. The Ct and Co can never be
random since they are dependent variables of Kt/V and prescription [75, 76]. These comments ignore publica-
tions over the past 15 years on conceptual modelingNPCR. A more realistic simulation was done by Ueh-
linger, who created data sets from random values for of continuous and intermittent clearance and variable
frequency intermittent dialysis therapy, which show thaturea generation and clearance and then computed Kt/V
and NPCR with three different distributions of V [74]. simplistic numerical addition of intermittent Kt/V values
is inappropriate [77–82].The V distributions were (mean 6 SD) V 5 40 6 0 L,
V 5 40 6 5 L, and V 5 40 6 10 L. The correlations The first kinetic extension of dose quantitation beyond
the domain of thrice weekly intermittent hemodialysisbetween NPCR and Kt/V showed r 5 0.02.44 and 0.82,
respectively, indicating that the correlation relates to the was the development of coefficients to combine the ef-
fects of continuous residual renal function and Kt/V onvariability in V. This analysis, along with the review by
Greene, Depner, and Daugirdas, indicates that a depen- the predialysis BUN in two and three times weekly he-
modialysis [77]. Subsequently, similar approaches weredence of NPCR on Kt/V cannot be unambiguously deter-
mined from cross-sectional data analysis caused by the used to define equivalency between CAPD clearance
normalized to Kt/V and Kt/V with thrice weekly hemodi-confounding effect of a normalized distribution of V
common to both parameters. However, longitudinal ob- alysis [78, 79]. More recently, these models have been
generalized to provide solutions for any combination ofservations in individual patients or groups of patients
will not be seriously compromised by this type of mathe- continuous and intermittent clearance [78–82].
All of these models have in common the definition ofmatical linkage.
a continuous clearance, which is considered to be theoreti-It is unfortunate that the statistical problems arising
cally equivalent to the sum of the intermittent clearancesout of cross-sectional analyses have led to much confu-
provided by intermittent dialysis therapy. In each model,sion about the NPCR and PCR. In individual patients,
a specific BUN point is chosen on the saw-toothed BUNwhen reasonable care is taken to avoid artifactual rela-
profile characteristic of intermittent dialysis therapy, andtionships, they provide valuable measures of protein in-
the level of continuous clearance required is calculatedtake in the stable outpatient. In more acute situations
to maintain the modeled BUN constant at this level at theand in the cases of intradialytic and parenteral nutritional
same NPCR. In this way, BUN per se is not a modelingsupport, the NPCR and PCR calculations combined with
parameter, but rather, the modeling point chosen is usedthe magnitude of amino acid administration provide an
to calculate a continuous clearance that will achieve aaccurate measure of nitrogen balance and assessment of
constant level of BUN that is equal to the modeled valuethe adequacy of the nutritional support program. Con-
at the same NPCR. In steady state with continuous clear-clusions that mathematical linkage in cross-sectional
ance, the relationship between urea generation (Gu, aanalysis invalidates the NPCR calculation in all instances
linear function of PCR), a steady-state BUN (Css), andare a bit like “throwing the baby out with the bath water.”
steady-state continuous urea clearance (Kss) is simply,
Gu 5 Kss(Css) (Eq. 4)MODELING VARIABLE FREQUENCY
INTERMITTENT DIALYSIS AND COMBINING Thus, the equivalent steady-state clearance is defined as:
INTERMITTENT WITH
Kss 5 Gu/Css (Eq. 5)CONTINUOUS CLEARANCE
There is a growing interest in home dialysis driven These relationships for the three models reported in
by attempts to provide more dialysis therapy through the literature are depicted schematically in Figure 12.
increasing the number of treatments per week and/or The peak concentration hypothesis [78] was proposed
by combining continuous ambulatory peritoneal dialysis to define the equivalency between the steady-state clear-
(CAPD) with intermittent hemodialysis. The prelimi- ance in CAPD and thrice weekly hemodialysis. The BUN
nary reports to date with more frequent dialysis are modeling point for equivalency was the peak predialysis
highly enthusiastic, and all report improved well-being BUN at the first dialysis of the week (Cpk), as shown in
and improvement in blood pressure control in those pa- Figure 12. For any given three times weekly intermittent
tients with intractable hypertension. Kt/V and Gu, the Cpk can be readily calculated, and the
The duration, frequency, and intensity of more fre- equivalent steady-state clearance (Kpkss) calculated by
appropriate substitution into equation 5.quent dialysis reported have varied a great deal. Levels
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Fig. 12. Three theoretical definitions of continuous urea clearance pro- Fig. 13. Interrelationships among eKt/V delivered each dialysis, num-
posed for modeling equivalency between hemodialysis and CAPD. ber of days dialyzed per week, and the level of weekly stdKt/V achieved.
The standard Kt/V (stdKt/V) hypothesis was based on a range of one to seven dialyses per week, with eKt/V
the assumption that the average predialysis BUN could for each dialysis ranging from 0.3 to 1.5. The continuous
be used to model the equivalent continuous clearance. clearance line shown is simply the eKt/V values multiplied
The stdKt/V model [80] was generalized so that a by seven and represents the weekly stdKt/V with contin-
unique mean predialysis BUN (Cm) could be computed uous dialysis. The family of curves clearly illustrates the
with any combination of Gu and continuous clearance nonlinear relationship between stdKt/V and eKt/V as
with variable frequency intermittent clearance. The equiv- eKt/V increases with no change in frequency of dialysis.
alent steady-state “standard” clearance (stdK) is then cal- Examination of the nitrogen (N) 5 3 curve shows the
culated by appropriate substitution into equation 5. stdKt/V increases from 0.5 to 2.3 as weekly eKt/V (each
The third definition of equivalency between continu- eKt/V times 3) increases from 0.9 to 1.5. Similarly, if we
ous and intermittent clearance has been called the equiv- examine the eKt/V 5 1.0 point as N increases from 2 to
alent renal clearance (EKR) [81, 82] and uses the time- 7, we see that stdKt/V increases from 1.3 to 4.3, while
averaged BUN or TAC as the equivalency modeling weekly eKt/V increases from 2.0 to 7.0.
concentration. A unique TAC value can be calculated Although these equivalency models must be consid-
for any combination of Gu and continuous clearance ered theoretical at present, one equivalency point can
with variable frequency intermittent clearance. The be evaluated from clinical experience. It is recommended
EKR is then calculated by appropriate substitution into that adequate CAPD requires a weekly stdKt/V of 2.0,
equation 5. as shown on Figure 13. An adequate eKt/V for three
Once the equivalent steady-state clearance is calcu- times weekly dialysis is 1.0 to 1.1 [30]. It can be seen in
lated, an equivalent steady-state Kt/V (ssKt/V) can be Figure 13 that there is close agreement between the
readily calculated by computing total clearance per day recommended dialysis dose for CAPD and for thrice
or week and dividing by V. It is important to re-empha- weekly hemodialysis when expressed as stdKt/V. The
size that, although a BUN point on the concentration peak concentration definition of continuous clearance
profile is chosen for modeling, the results of these contin- would predict a ssKt/V of 1.75 for CAPD, which is now
uous clearance models are totally independent of BUN believed to be too low. In contrast, the TAC criterion
concentration because they calculate clearance from for continuous clearance would require a ssKt/V of 3.0
Gu/Cu as shown in equation 5 and simply determine for equivalency to thrice weekly hemodialysis. Thus, the
the continuous clearance, which will give an equivalent stdKt/V provides a clinically accepted measure of dose
concentration at the same generation rate as intermittent equivalency between CAPD and thrice weekly hemodi-
therapy. As in the case of Kt/V for three times weekly alysis without undue violence required to “fit the data to
dialysis, these continuous clearance model analogues a procrustean bed” [76].
also define generic clearances for low molecular weight
solutes using urea as a generic solute.
REVIEW OF REPORTED STUDIES OF MOREThe relationships between the number of dialyses per
FREQUENT DIALYSESweek, the intensity of each dialysis (expressed as eKt/V),
and the stdKt/V achieved are depicted in Figure 13. In Although the loci of adequate dialysis for CAPD and
thrice weekly dialysis in Figure 13 agree well, they doFigure 13, the results of model solution are shown over
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is uncertainty about the lower doses because review of
the data shown in Figure 14 with short t and eKt/V in the
range of 0.4 to 0.6 shows that in all instances, approxima-
tion equations and/or dialysate urea collections were
used without consideration of the large double-pool ki-
netic effects on these Kt/V and NPCR calculations.
These are not appropriate measurement techniques to
use with low levels of delivered Kt/V and short treatment
times since, as discussed previously in this article, there
will be both marked underestimation of V and rebound,
which must be accounted for in analyzing the delivered
Kt/V and the calculated NPCR—both Kt/V and NPCR
will be substantially overestimated without correction of
the data for volume error and rebound.
Fig. 14. Distribution of stdKt/Vs calculated for seven studies of in- The wide distribution of therapy levels in Figure 14creased dialysis frequency.
but good short-term soft data outcome reports (primarily
improved patient well being) with all reported treat-
ments indicate the strong need for a prospectively ran-
domized and controlled trial of more frequent dialysisnot establish a generalized validity of the stdKt/V model.
To explore this question further, Figure 14 illustrates the therapy over a well-defined range of doses. It would
seem important to determine whether a stdKt/V of 2.5stdKt/V values calculated for seven reported studies of
dialysis with dialysis frequency (N) four to six times per with eKt/V 0.9 four days per week and t two hours [79]
has an equivalent outcome to the much more demandingweek. The therapies are shown as filled squares, and the
studies reported are identified by reference number. The therapy with eKt/V 1.2 to 1.5 over eight hours six days
per week and providing stdKt/V 4 to 4.5 [80, 81], or afirst report was the Bonomini study [83]. Bonomini et
al compared two, three, and five dialyses per week, and similar high stdKt/V of four provided by eKt/V 1.5 over
three to four hours six times per week. Hard data suchfound a major improvement when the number (N) in-
creased from two to three and minimal further improve- as mortality, hospitalization rates and long-term compli-
cation rates will be required for reliable comparativement from three to five. The eKt/V calculated per treat-
ment fell from 0.9 with N 5 2 to 0.5 with N 5 5. Note evaluation of the broad spectrum of therapies portrayed
in Figure 14.the stdKt/V increased from a very inadequate level of
1.2 with N 5 2 to a level of 2.2 with N 5 5. Thus, although Urea should not be the only solute used to model
these more frequent therapies. It is of considerable im-there was minimal change in weekly summed eKt/V,
there was a marked increase in stdKt/V from a level portance to not limit Kt/V analyses to urea in the concep-
tual approach to modeling variable frequency dialysisassociated with greatly increased mortality (1.2) to the
currently defined level of adequate therapy (2.2). therapy. Kt/V is a generalizable kinetic parameter and
can be appropriately used to describe the magnitude ofNote that four of the reports shown in Figure 14 pro-
vided quite low eKt/V levels per treatment in the range removal and clearance of any solute. Equilibrated Kt/V
levels achieved for b2m, for example, would be of greatof 0.4 to 0.6 with short t approximately two hours and
N 5 5 to 6 treatments per week [83–86]. It is interesting importance to compare in different treatment schedules.
It is mandatory that K, Ca, intercellular P, acid-base andto note that the stdKt/V levels with these four studies
are nearly identical to that calculated for long eight-hour Na, and water balance control and oscillation also be
carefully monitored and compared. New conceptualdialyses three times weekly in Tassin [53]. The other
three reported studies delivered higher eKt/V per treat- models and clinical protocols will be required to quanti-
tate the effect of dialysis frequency and intensity onment ranging from 1.0 to 1.5 with N four to six times
per week [87–89]. Two of these [88, 89] delivered much oscillation of Na and water balance and acid-base bal-
ance during intermittent dialysis. Minimizing departureshigher stdKt/V levels of 4.0 to 4.5 because of high eKt/V
with long treatment time and six dialyses per week, while from steady state are often cited as possible advantages
of more frequent dialysis therapy, but to date, thesein the other study [87], the eKt/V was 0.95, and t was
about two hours, which provided stdKt/V comparable fluctuations have only been considered qualitatively as
“unphysiology.” It is possible, for example, that smallto the low eKt/V studies [81–86].
It is apparent in Figure 14 that the stdKt/V levels patients will benefit more than large patients from daily
dialysis, since positive interdialytic water and Na balanceachieved in studies of more frequent dialysis reported
to date vary widely, ranging from 2.1 to 4.7, a 5 to 235% is often greater relative to size in small patients in our
experience.increase over a reference stdKt/V of 2.0. However, there
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(SK) hemodialyzers. Trans Am Soc Artif Intern Organs 18:113–121,Nutrition may be a key outcome measure, and NPCR
1972
should be accurately measured with appropriate atten- 19. Scribner B: Discussion. Trans Am Soc Artif Intern Organs 11:29,
1965tion to double-pool effects along with other nutritional
20. Babb L, Popovich R, Christopher T, Scribner B: The genesis ofparameters. To date, the studies have reported mostly
the square-meter hour hypothesis. Trans Am Soc Artif Intern Or-
diet surveys that often suggest that patients are following gans 18:81–81, 1971
21. Babb L, Strand M, Uvelli D, Mulutinovic J, Scribner B: Quanti-much less restricted diets. This was also reported in the
tative description of dialysis treatment: A dialysis index. Kidneyearly days of CAPD, but dietary protein intake when
Int 7(Suppl 2):S23–S30, 1974
measured by NPCR or urea excretion is not high in PD 22. Gotch F: Kinetic modeling in hemodialysis, in Clinical Dialysis
(3rd ed), edited by Nissenson A, Fine R, Gentile D, Norwalk,patients. It is likely that the time is now right for more
Appleton and Lange, 1995, pp 156–189studies of daily hemodialysis. It is hoped that these stud-
23. Gotch F, Krueger K: Adequacy of Dialysis. Kidney Int 7(Suppl
ies will take the form of randomized trials guided by 2):S1–S263, 1975
24. Lowrie E, Laird N: Cooperative dialysis study. Kidney Intappropriate kinetic modeling of therapy-based and new
23(Suppl 13):S1–S122, 1983hypotheses regarding treatment frequency-dependent
25. Sargent J, Gotch F: Principles and biophysics of dialysis, in Re-
uremic toxicity. placement of Renal Function by Dialysis (4th ed), edited by Jacobs
C, Kjellstrand C, Koch K, Winchester J, Dordrecht, Kluwer
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